Caspase 9b: a new target for therapy in non-small-cell lung cancer

References

• Walker S. Updates in non-small cell lung cancer. Clin. J. Oncol. Nurs.12(4), 587–596 (2008).
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med.2(3), e73 (2005).
   PubMed Web of Science ®Google Scholar
• Kampa D, Cheng J, Kapranov P et al. Novel RNAs identified from an in-depth analysis of the transcriptome of human chromosomes 21 and 22. Genome Res.14(3), 331–342 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson JM, Castle J, Garrett-Engele P et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science (New York, NY)302(5653), 2141–2144 (2003).
   Google Scholar
• Venables JP. Aberrant and alternative splicing in cancer. Cancer Res.64(21), 7647–7654 (2004).
   PubMed Web of Science ®Google Scholar
• Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol.14(3), 185–193 (2007).
   PubMed Web of Science ®Google Scholar
• Cheng C, Sharp PA. Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol. Cell Biol.26(1), 362–370 (2006).
   PubMed Web of Science ®Google Scholar
• Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol. Cell33(5), 591–601 (2009).
   PubMed Web of Science ®Google Scholar
• Valacca C, Bonomi S, Buratti E et al. Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J. Cell Biol.191(1), 87–99 (2010).
   PubMedGoogle Scholar
• Groeger AM, Esposito V, De Luca A et al. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology44(1), 54–63 (2004).
   PubMed Web of Science ®Google Scholar
• Karczmarek-Borowska B, Filip A, Wojcierowski J et al. Estimation of prognostic value of Bcl-xL gene expression in non-small cell lung cancer. Lung Cancer (Amsterdam, The Netherlands)51(1), 61–69 (2006).
   PubMed Web of Science ®Google Scholar
• Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit. Rev. Clin. Lab. Sci.39(6), 527–579 (2002).
   PubMed Web of Science ®Google Scholar
• Shultz JC, Goehe RW, Wijesinghe DS et al. Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res.70(22), 9185–9196 (2010).
   PubMed Web of Science ®Google Scholar
• Goehe RW, Shultz JC, Murudkar C et al. hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing. J. Clin. Investig.120(11), 3923–3939 (2010).
   PubMed Web of Science ®Google Scholar
• Ebert AD, Chen F, He X, Cryns VL, Bohn MC. A tetracycline-regulated adenovirus encoding dominant-negative caspase-9 is regulated in rat brain and protects against neurotoxin-induced cell death in vitro, but not in vivo. Exp. Neurol.191(Suppl. 1), S80–S94 (2005).
   Google Scholar
• Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis9(6), 691–704 (2004).
   PubMed Web of Science ®Google Scholar
• Kominsky DJ, Bickel RJ, Tyler KL. Reovirus-induced apoptosis requires mitochondrial release of Smac/DIABLO and involves reduction of cellular inhibitor of apoptosis protein levels. J. Virol.76(22), 11414–11424 (2002).
   PubMed Web of Science ®Google Scholar
• Liang Q, Liou AK, Ding Y et al. 6-Hydroxydopamine induces dopaminergic cell degeneration via a caspase-9-mediated apoptotic pathway that is attenuated by caspase-9dn expression. J. Neurosci. Res.77(5), 747–761 (2004).
   PubMedGoogle Scholar
• Philchenkov A, Zavelevich M, Kroczak TJ, Los M. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp. Oncol.26(2), 82–97 (2004).
   PubMed Web of Science ®Google Scholar
• Seol DW, Billiar TR. A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J. Biol. Chem.274(4), 2072–2076 (1999).
   PubMed Web of Science ®Google Scholar
• Soengas MS, Alarcon RM, Yoshida H et al. APAF-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science (New York, NY)284(5411), 156–159 (1999).
   Google Scholar
• Srinivasula SM, Ahmad M, Guo Y et al. Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. Cancer Res.59(5), 999–1002 (1999).
   PubMed Web of Science ®Google Scholar
• Stephanou A, Scarabelli TM, Knight RA, Latchman DS. Antiapoptotic activity of the free caspase recruitment domain of procaspase-9: a novel endogenous rescue pathway in cell death. J. Biol. Chem.277(16), 13693–13699 (2002).
   PubMedGoogle Scholar
• Wu GS, Ding Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene21(1), 1–8 (2002).
   PubMedGoogle Scholar
• Yacoub A, Mitchell C, Hong Y et al. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol. Ther.3(8), 739–751 (2004).
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Ann. Rev. Med.55, 433–457 (2004).
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol.22(16), 3238–3247 (2004).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L et al. SATURN: a double-blind, randomized, Phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J. Clin. Oncol.27, 15s (2009).
   Web of Science ®Google Scholar
• Tockman MS, Mulshine JL, Piantadosi S et al. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin. Cancer Res.3(12 Pt 1), 2237–2246 (1997).
   PubMed Web of Science ®Google Scholar
• Sueoka E, Sueoka N, Iwanaga K et al. Detection of plasma hnRNP B1 mRNA, a new cancer biomarker, in lung cancer patients by quantitative real-time polymerase chain reaction. Lung Cancer (Amsterdam, The Netherlands)48(1), 77–83 (2005).
   PubMed Web of Science ®Google Scholar
• Boukakis G, Patrinou-Georgoula M, Lekarakou M, Valavanis C, Guialis A. Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues. BMC Cancer10, 434 (2010).
   PubMed Web of Science ®Google Scholar